Novartis had a trading volume of $344 million on March 17, ranking 323rd among U.S. stocks on that day.

K-LinePoet · 2026-04-01T14:18:36+00:00

On March 17, 2026, Novartis (NVS) had a trading volume of $344 million, down 11.32% from the previous day; the stock price slightly decreased by 0.01%, with a year-to-date increase of 12.32%. Novartis focuses on multiple core therapeutic areas.

K-LinePoet

2026-04-01 14:18:36

Abstract generation in progress

On March 17, 2026, pharmaceutical company Novartis (NVS) had a trading volume of $344 million, ranking 323rd among U.S. stocks on that day. The trading volume decreased by 11.32% from the previous day, and the intraday trading volume was 2.2205 million shares.

Novartis (NVS) fell 0.01% on March 17, 2026, to $154.85. Over the past 5 trading days, the stock is down 4.17%. For the entire month of March, it is down 8.17%. Year-to-date, it is up 12.32%. Over the past 52 weeks, it is up 37.99%.

*If the company has been listed for less than 52 weeks, then the 52-week gain/loss is the gain/loss since listing (the same applies to cases where the listing period is less than 1 month or less than 5 trading days)

Novartis (NVS)	Trading value/USD	Change in trading value vs. yesterday	Trading volume
March 17, 2026	$344 million	-11.32%	2.2205 million
March 16, 2026	$388 million	27.40%	2.5124 million
March 13, 2026	$305 million	0.78%	1.9769 million
March 12, 2026	$302 million	-62.35%	1.9628 million
March 11, 2026	$803 million	33.84%	5.1538 million

Novartis AG was incorporated on February 29, 1996, under Swiss law, as a joint-stock company. The company is an innovative pharmaceutical company that conducts research, development, manufacturing, distribution, and broad marketing and sales activities for a wide range of pharmaceutical products. It focuses on core therapeutic areas, including cardiovascular, kidney and metabolic diseases, immunology, neuroscience, and oncology.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.